Telatinib

Overview

Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2 , VEGFR3 , PDGFα , and c-Kit with IC 50 s of 6, 4, 15 and 1 nM, respectively.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > VEGFR

Product Information

• Catalog No.: HY-10527
• CAS No.: 332012-40-5
• Molecular Formula: C20H16ClN5O3
• Molecular Weight: 409.83
• Purity: 99.37%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (5.08 mM); Clear solution
• Availability: In-stock

Source

Original product source